Biotech IV Monitor

TGTX — TG Therapeutics Inc.

$8.6B market cap · 6 upcoming readouts tracked

Clinical trial readout dates for TG Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.

Next readoutJanuary 2027in ~2 months
Upcoming readouts63 Phase 3
Market cap$8.6B
Cash & investments$557Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-09

Upcoming readouts

Phase 3 Ublituximab
Relapsing Multiple Sclerosis · NCT05877963
January 2027
Recruiting
Phase 2 Ublituximab
Multiple Sclerosis · NCT07503873
July 2027
Recruiting
Phase 2 Ublituximab
Myasthenia Gravis · NCT07673744
July 2028
Recruiting
Phase 2 Ublituximab
Schizophrenia · NCT07680946
December 2028
Recruiting
Phase 2/3 Ublituximab
Relapsing Multiple Sclerosis · NCT07220252
January 2030
Recruiting
Phase 3 Ublituximab
Relapsing Multiple Sclerosis (RMS) · NCT04130997
May 2032
Ongoing

Cash position

TG Therapeutics Inc. reported $557M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). It reported net income of $55M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-09

Companies working on similar indications

Discussion

No messages yet. If you follow TGTX, you can start the conversation.
Track TGTX in real time
See live implied volatility for TGTX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on TGTX
Contact — questions or corrections about TGTX: dukeupt@gmail.com